The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
Open accessAbstract
Disease overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus and risk of leukemic or fibrotic transformation. Diagnosis: Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2, CALR or MPL mutations (so called driver mutations). In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. Survival: Median survivals are approximately 15 years for PV and 18 years for ET; the corresponding values for patients age 40 or younger were 37 and 35 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life‐expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET but risk of thrombosis is higher in JAK2 mutated cases. Leukemic transformation rates at 10 years are estimated at <1% for ET and 3% for PV. Thrombosis risk: In PV, two risk categories are considered: high (age > 60 years or thrombosis history present) and low (absence of both risk factors). In ET, four risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (age > 60 years, no thrombosis history, JAK2 wild‐type) and high (thrombosis history present or age > 60 years with JAK2 mutation). Risk‐adapted therapy: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once‐daily or twice‐daily aspirin (81 mg), in the absence of contraindications. Very low risk ET might not require therapy while aspirin therapy is advised for low risk disease. Cytoreductive therapy is recommended for high‐risk ET and PV, but it is not mandatory for intermediate‐risk ET. First‐line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second‐line drugs of choice are interferon‐α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs. New treatment directions: Controlled studies are needed to confirm the clinical outcome value of twice‐daily vs once‐daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Self-citationHydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Self-citationHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Self-citationTefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationBarbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 641
Self-citationBarbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Self-citationRumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A. S., Milosevic, J. D., Them, N. C. C., Berg, T., Elena, C., Casetti, I. C., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539098 · Cited by 602
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 548
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citationBarosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationIncreased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy
Berk, P. D., Goldberg, J. D., Silverstein, M. N., Weinfeld, A., Donovan, P. B., Ellis, J. T., Landaw, S. A., Laszlo, J., Najean, Y., Pisciotta, A. V., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102193040801 · Cited by 492
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
Elliott, M. A., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05277.x · Cited by 473
Self-citationCarobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Vannucchi, A. M., Antonioli, E., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339002 · Cited by 456
Self-citationFinazzi, G. (2005) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 431
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Rotunno, G., Mannarelli, C., Guglielmelli, P., Pacilli, A., Pancrazzi, A., Pieri, L., Fanelli, T., Bosi, A., & Vannucchi, A. M. (2014) · Blood · doi:10.1182/blood-2013-11-538983 · Cited by 416
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3471 · Cited by 373
Sterkers, Y., Preudhomme, C., Laı̈, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 372
Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370
Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30236-4 · Cited by 367
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Self-citationGisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H.-M., Kralovics, R., & Petrides, P. E. (2013) · Blood · doi:10.1182/blood-2012-07-443770 · Cited by 330
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311
Self-citationWolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Self-citationPardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 294
Self-citationBarbui, T., Vannucchi, A. M., Buxhofer-Ausch, V, De Stefano, V, Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.94 · Cited by 283
Self-citationPassamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Kvasnicka, H. M., Ruggeri, M., Randi, M. L., Gangat, N., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403279 · Cited by 277
Self-citationKiladjian, J.-J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J.-D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0792 · Cited by 255
Alvarez-Larrán, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V., Hernández-Boluda, J.-C., Ayats, R., Salvador, C., Muntañola, A., Bellosillo, B., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263319 · Cited by 244
Fruchtman, S. M., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D., & Wasserman, L. R. (1997) · PubMed · Cited by 239
Alvarez-Larrán, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J.-C., Ferrer-Marín, F., Angona, A., Gómez, M., Muiña, B., Guillén, H., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387787 · Cited by 234
Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., Sordi, B., Szuber, N., Rotunno, G., Pacilli, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16380 · Cited by 231
Self-citationPascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., Pocaterra, D., Ragazzoni, E., Rolandi, G., Rocca, B., et al. (2012) · Blood · doi:10.1182/blood-2011-06-359224 · Cited by 222
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., et al. (2008) · Blood · doi:10.1182/blood-2008-01-135897 · Cited by 222
Self-citationTefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 217
Self-citationTefferi, A., Wassie, E. A., Guglielmelli, P., Gangat, N., Belachew, A. A., Lasho, T. L., Finke, C., Ketterling, R. P., Hanson, C. A., Pardanani, A., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23743 · Cited by 213
Self-citationGangat, N., Wolanskyj, A. P., McClure, R. F., Li, C.-Y., Schwager, S., Wu, W., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404500 · Cited by 208
Self-citationTefferi, A., & Elliott, M. (2007) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-976165 · Cited by 197
Self-citationGisslinger, H., Zagrijtschuk, O., Buxhofer-Ausch, V., Thaler, J., Schloegl, E., Gastl, G. A., Wolf, D., Kralovics, R., Gisslinger, B., Strecker, K., et al. (2015) · Blood · doi:10.1182/blood-2015-04-637280 · Cited by 193
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24221 · Cited by 177
Self-citationYacoub, A., Mascarenhas, J., Kosiorek, H., Prchal, J. T., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., et al. (2019) · Blood · doi:10.1182/blood.2019000428 · Cited by 177
Self-citationTefferi, A., & Pardanani, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816082 · Cited by 175
Self-citationRuxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., Houlton, A., Alimam, S., Ewing, J., Wood, M., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785790 · Cited by 174
Michiels, J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U., & van Vliet, H. V. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-949664 · Cited by 169
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
Kiladjian, J.-J., Chomienne, C., & Fenaux, P. (2008) · Leukemia · doi:10.1038/leu.2008.280 · Cited by 169
Szuber, N., Mudireddy, M., Nicolosi, M., Penna, D., Vallapureddy, R. R., Lasho, T. L., Finke, C., Begna, K. H., Elliott, M. A., Hook, C. C., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.022 · Cited by 168
Self-citationBarbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., et al. (2014) · Blood · doi:10.1182/blood-2014-07-591610 · Cited by 161
Self-citationBarbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009) · Blood · doi:10.1182/blood-2009-02-206797 · Cited by 159
Self-citationDiagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz, P., Girodon, F., Donnard, M., Latger‐Cannard, V., Dobo, I., Boiret, N., Lecron, J., Binquet, C., Barro, C. D., Hermouet, S., et al. (2004) · PubMed · Cited by 156
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Guglielmelli, P., Pancrazzi, A., Bergamaschi, G., Rosti, V., Villani, L., Antonioli, E., Bosi, A., Barosi, G., & Vannucchi, A. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06565.x · Cited by 153
Cerquozzi, S., Barraco, D., Lasho, T. L., Finke, C. M., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., & Tefferi, A. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0035-6 · Cited by 152
Self-citationMasked polycythemia Vera (mPV): Results of an international study
Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Carobbio, A., Rumi, E., Randi, M. L., Betozzi, I., Vannucchi, A. M., Pieri, L., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23585 · Cited by 151
Self-citationNajean, Y., & Rain, J. (1997) · Blood · doi:10.1182/blood.v89.7.2319 · Cited by 149
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J. L., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404069 · Cited by 144
Tefferi, A., & Fonseca, R. (2002) · Blood · doi:10.1182/blood.v99.7.2627 · Cited by 127
Self-citationBarbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Vannucchi, A. M., & Tefferi, A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.06.001 · Cited by 127
Self-citationJAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
Pardanani, A. D., Vannucchi, A. M., Passamonti, F., Cervantes, F., Barbui, T., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.269 · Cited by 125
Self-citationSchmitt-Graeff, A. H., Teo, S.-S., Olschewski, M., Schaub, F. X., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U., & Skoda, R. C. (2007) · Haematologica · doi:10.3324/haematol.11581 · Cited by 121
Polycythemia Vera and the Myeloproliferative Disorders
Petitt, R. M. (1995) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63955-4 · Cited by 120
GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
Mead, A. J., Rugless, M. J., Jacobsen, S. E. W., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1200349 · Cited by 117
Calreticulin mutations and long-term survival in essential thrombocythemia
Tefferi, A., Wassie, E. A., Lasho, T. L., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., Pardanani, A. D., Gangat, N., & Wolanskyj, A. P. (2014) · Leukemia · doi:10.1038/leu.2014.148 · Cited by 116
Self-citationEvidence and expertise in the management of polycythemia vera and essential thrombocythemia
Finazzi, G., & Barbui, T. (2008) · Leukemia · doi:10.1038/leu.2008.177 · Cited by 112
Self-citationBoyd, E. M., Bench, A. J., Goday‐Fernández, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08083.x · Cited by 106
Rocca, B., Tosetto, A., Betti, S., Soldati, D., Petrucci, G., Rossi, E., Timillero, A., Cavalca, V., Porro, B., Iurlo, A., et al. (2020) · Blood · doi:10.1182/blood.2019004596 · Cited by 106
Szuber, N., Vallapureddy, R. R., Penna, D., Lasho, T. L., Finke, C. M., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., & Tefferi, A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25270 · Cited by 99
Self-citationPresence of calreticulin mutations in JAK2-negative polycythemia vera
Broséus, J., Park, J.-H., Carillo, S., Hermouet, S., & Girodon, F. (2014) · Blood · doi:10.1182/blood-2014-06-583161 · Cited by 98
Barbui, T., Vannucchi, A. M., Finazzi, G., Finazzi, M. C., Masciulli, A., Carobbio, A., Ghirardi, A., & Tognoni, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24851 · Cited by 90
Self-citationBarbui, T., Thiele, J., Carobbio, A., Guglielmelli, P., Rambaldi, A., Vannucchi, A. M., & Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23694 · Cited by 84
Self-citationSant’Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25677 · Cited by 83
Self-citationFinazzi, G., Carobbio, A., Guglielmelli, P., Cavalloni, C., Salmoiraghi, S., Vannucchi, A. M., Cazzola, M., Passamonti, F., Rambaldi, A., & Barbui, T. (2014) · Blood · doi:10.1182/blood-2014-08-596676 · Cited by 82
Self-citationÁlvarez‐Larrán, A., Martinez-Aviles, L. M., Hernández‐Boluda, J. C., Ferrer‐Marín, F., Antelo, M. L., Burgaleta, C., Mata, M. I., Xicoy, B., Martínez‐Trillos, A., Gómez‐Casares, M. T., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2152-7 · Cited by 81
Bonicelli, G., Abdulkarim, K., Mounier, M., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12117 · Cited by 81
Patnaik, M. M., & Tefferi, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24637 · Cited by 81
Self-citationGrießhammer, M., Struve, S., & Harrison, C. N. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-942763 · Cited by 78
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76
Liu, K., Martini, M., Rocca, B., Amos, C. I., Teofili, L., Giona, F., Ding, J., Komatsu, H., Larocca, L. M., & Skoda, R. C. (2009) · Haematologica · doi:10.3324/haematol.2009.005918 · Cited by 60
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
Shvidel, L., Sigler, E., Haran, M. Z., Klepfish, A., Duek, A., Berrébi, A., & Shtalrid, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404743 · Cited by 55
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Elala, Y. C., Lasho, T. L., Gangat, N., Finke, C. M., Barraco, D., Haider, M., Hussein, A. K. A., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24338 · Cited by 55
Self-citationBarosi, G., Tefferi, A., Besses, C., Birgegård, G., Cervantes, F., Finazzi, G., Gisslinger, H., Grießhammer, M., Harrison, C. N., Hehlmann, R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.250 · Cited by 54
Self-citationGender and survival in essential thrombocythemia: A two‐center study of 1,494 patients
Tefferi, A., Betti, S., Barraco, D., Mudireddy, M., Shah, S. H., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., Coltro, G., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24882 · Cited by 46
Self-citationPatnaik, M. M., & Tefferi, A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25397 · Cited by 46
Self-citationAbatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
Östör, A. J. K. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0964-3 · Cited by 39
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Kuriakose, E. T., Gjoni, S., Wang, Y. L., Baumann, R., Jones, A. V., Cross, N. C. P., & Silver, R. T. (2013) · Haematologica · doi:10.3324/haematol.2013.087742 · Cited by 37
Mascarenhas, J. O., Prchal, J. T., Rambaldi, A., Mesa, R. A., Berenzon, D. P., Yacoub, A., Harrison, C. N., McMullin, M. F., Vannucchi, A. M., Ewing, J. C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.479.479 · Cited by 31
Self-citationSerrao, A., Breccia, M., Napolitano, M., Fiori, L., Santoro, M., Scalzulli, E., Santopietro, M., Santoro, C., Raso, S., & Chistolini, A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25990 · Cited by 22
Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction
Tefferi, A. (2008) · Acta Haematologica · doi:10.1159/000140629 · Cited by 9
Self-citationErythrocytosis associated with cerebral hemangiomas and multiple venous anomalies
Gangat, N., Pardanani, A. D., & Tefferi, A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25913 · Cited by 7
Self-citation
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Metadata
- Authors
- Tefferi, A., & Barbui, T.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2020-10-23
- Volume
- 95
- Issue
- 12
- Pages
- 1599-1613
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3088307847
- Cited by
- 352
- References
- 100
- FWCI
- 23.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.